Similarly to observations reported in colon cancer cells, we found inhibition of the MAPK/ERK signalling pathway by MEK1/2-specific inhibitor U0126 to reduce SP, possibly through altering ABCG2 expression or localisation [42]. This evidence concerns the gene MAPK1 and colonic neoplasm.